Epstein-Barr virus nuclear antigen 2 (EBNA2)

Epstein-Barr virus nuclear antigen 2 (EBNA2) is a primary viral transcription factor and the master regulator of the Epstein-Barr virus (EBV) growth-transformation program [1, 8]. It is one of the first proteins expressed upon infection of resting B lymphocytes and is essential for their transformation into immortalized lymphoblastoid cell lines [9, 14]. EBNA2 does not bind DNA directly; instead, it functions as a transactivator by hijacking host DNA-binding proteins, most notably RBP-Jκ (CBF1), to mimic constitutively active Notch signaling [12, 17]. This recruitment facilitates the expression of viral latent membrane proteins (LMP1, LMP2) and host genes involved in cell cycle progression and activation, such as MYC and CD23 [3, 12, 16]. Beyond B-cell transformation, EBNA2 contributes to immune evasion by downregulating immune checkpoint ligands and microRNAs that would otherwise trigger an anti-tumor response [10, 11]. In the context of disease, EBNA2 is central to the pathogenesis of various EBV-associated malignancies, including Burkitt and Hodgkin lymphomas, particularly in immunocompromised patients [3, 10]. While currently lacking FDA-approved clinical inhibitors, EBNA2 is an active target of research, with experimental strategies focusing on promoting its degradation via arsenic trioxide or blocking its essential interaction with host adaptors using peptidomimetics [2, 4, 18].

Other names

EBNA-2Epstein-Barr nuclear antigen 2EBV nuclear antigen 2HHV-4 nuclear antigen 2

Promotion of proteasomal degradation (Arsenic trioxide); Inhibition of protein-protein interaction with RBP-Jκ/CBF1 (EBNA2-TAT peptide); Inhibition of viral protein translation (Silvestrol)